Immunodeficiency clinical trials at UC Davis
3 research studies open to eligible people
Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
open to all eligible people
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Sacramento, California and other locations
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
“Study looking at stem cell gene therapy to treat patients with HIV and lymphoma”
open to eligible people ages 18 years and up
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Sacramento, California and other locations
Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 16 years and up
The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.
San Francisco, California and other locations
Our lead scientists for Immunodeficiency research studies include Mehrdad Abedi, MD.